This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AbbVie's Deal for Shire Benefits Investors in More Ways Than One

NEW YORK (TheStreet) -- Better product diversification and an extensive drug pipeline have been at the top of AbbVie's (ABBV - Get Report) priority list ever since the drug giant was spun out of Abbott Labs (ABT) at the beginning of last year.

With AbbVie moving closer Monday to securing its deal for Shire (SHPG - Get Report), which will also come with significant tax savings, management looks to kill multiple birds with one stone. And patient investors who want higher profits and a boost in shareholder returns will be rewarded.

Why JPMorgan Is Undervalued on Long-Term Earnings Growth Estimates

Low-Interest Rates Woes? High-Yield Closed-End Funds May Be the Cure

There's now confirmation that both AbbVie and Shire have entered "detailed discussions." This comes on the heels of AbbVie having -- yet again -- raised its offer from $51.5 billion to $53.68 billion. This is now AbbVie's fifth offer. The two firms have danced since AbbVie's original offer of $46.5 billion was rebuffed.

At this point, it's not a matter of "if" a deal happens, it's a matter of "when." When the deal is done, AbbVie's stock should head toward the $70 level in the next 12 to 18 months, representing gains of close to 30%.

For that matter, a price target of $77.50 by 2016, which suggests gains of 42%, is also achievable. This is assuming that AbbVie follows through with plans to reincorporate in the British Island of Jersey, Shire's current headquarters. At that point, AbbVie, currently headquarter in Illinois, will only have to pay the U.K.'s 13% corporate tax rate, sheltering it from the United States' 35% corporate tax rate.

The tax savings, which will boost earnings, is central to the story. Not to mention, the deal immediately bolsters its pipeline. My $70 target is $1 more than the $69 price, which is currently AbbVie's highest analyst target

AbbVie shares, which are up 6% on the year to date, have shed 6% since reaching an intraday high of $58.27 two weeks ago. AbbVie was up $55.02, or 6 cents, near the Monday close. Shire was up about 2%.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ABBV $63.86 -1.27%
SHPG $239.19 -1.98%
AAPL $125.80 -2.25%
FB $77.56 -1.59%
GOOG $530.80 -1.85%

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs